MY200348A - Crystalline forms of a jak inhibitor compound - Google Patents

Crystalline forms of a jak inhibitor compound

Info

Publication number
MY200348A
MY200348A MYPI2019005859A MYPI2019005859A MY200348A MY 200348 A MY200348 A MY 200348A MY PI2019005859 A MYPI2019005859 A MY PI2019005859A MY PI2019005859 A MYPI2019005859 A MY PI2019005859A MY 200348 A MY200348 A MY 200348A
Authority
MY
Malaysia
Prior art keywords
crystalline forms
inhibitor compound
crystalline
jak inhibitor
hydrates
Prior art date
Application number
MYPI2019005859A
Other languages
English (en)
Inventor
Glenn D Crater
Melanie A Kleinschek
Jerry Nzerem
Marta Dabros
Venkat R Thalladi
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of MY200348A publication Critical patent/MY200348A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI2019005859A 2017-05-01 2018-04-30 Crystalline forms of a jak inhibitor compound MY200348A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762492571P 2017-05-01 2017-05-01
PCT/US2018/030144 WO2018204236A1 (en) 2017-05-01 2018-04-30 Crystalline forms of a jak inhibitor compound

Publications (1)

Publication Number Publication Date
MY200348A true MY200348A (en) 2023-12-21

Family

ID=62165729

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019005859A MY200348A (en) 2017-05-01 2018-04-30 Crystalline forms of a jak inhibitor compound

Country Status (13)

Country Link
US (1) US10251874B2 (cg-RX-API-DMAC7.html)
EP (1) EP3619208B1 (cg-RX-API-DMAC7.html)
JP (1) JP7096268B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200003121A (cg-RX-API-DMAC7.html)
CN (1) CN110603255B (cg-RX-API-DMAC7.html)
AU (1) AU2018261591B2 (cg-RX-API-DMAC7.html)
CA (1) CA3059790A1 (cg-RX-API-DMAC7.html)
MX (1) MX389014B (cg-RX-API-DMAC7.html)
MY (1) MY200348A (cg-RX-API-DMAC7.html)
PH (1) PH12019502425A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201909376TA (cg-RX-API-DMAC7.html)
TW (1) TWI808083B (cg-RX-API-DMAC7.html)
WO (1) WO2018204236A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI710560B (zh) 2015-11-03 2020-11-21 美商施萬生物製藥研發Ip有限責任公司 用於治療呼吸疾病之jak激酶抑制劑化合物
TWI754019B (zh) 2017-03-09 2022-02-01 美商施萬生物製藥研發 Ip有限責任公司 含有4員雜環醯胺之jak抑制劑
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
AU2018261588A1 (en) 2017-05-01 2019-10-31 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
BR112021004063A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc amidas heterocíclicas com 5 a 7 membros como inibidores de jak
BR112021004087A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc processo para preparar inibidores de jak e seus intermediários
DK3837258T3 (da) 2018-09-04 2024-07-22 Theravance Biopharma R&D Ip Llc Dimethyl amino azetidine amides as jak inhibitors
EP3853229A1 (en) 2018-10-29 2021-07-28 Theravance Biopharma R&D IP, LLC 2-azabicyclo hexane compound as jak inhibitor
KR20220149585A (ko) 2020-03-02 2022-11-08 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제 화합물의 결정성 수화물
CA3212635A1 (en) * 2021-03-26 2022-09-29 Theravance Biopharma R&D Ip, Llc Crystalline form of a dihydrochloride salt of a jak inhibitor compound
TW202317550A (zh) 2021-06-25 2023-05-01 美商施萬生物製藥研發 Ip有限責任公司 作為jak抑制劑之咪唑吲唑化合物
CN118401508A (zh) * 2021-12-17 2024-07-26 株式会社大熊制药 (2R,3S)-2-(3-(4,5-二氯-1H-苯并[d]咪唑-1-基)丙基)哌啶-3-醇的新酸加成盐及晶形

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7872014B2 (en) 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ttk阻害作用を有するインダゾール誘導体
CA2756989A1 (en) 2009-04-03 2010-10-07 Douglas Burdi Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
SMT201700581T1 (it) 2009-12-21 2018-01-11 Samumed Llc 1h-pirazolo[3,4-b]piridine e loro usi terapeutici
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
LT3077395T (lt) 2013-12-05 2018-02-12 Pfizer Inc. Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai
PE20161475A1 (es) 2014-05-14 2017-01-08 Pfizer Pirazolopiridinas y pirazolopirimidinas
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
DK3712152T3 (da) 2015-11-03 2021-03-22 Topivert Pharma Ltd 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus kinase-inhibitorer
EP3831830A1 (en) 2015-11-03 2021-06-09 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
TWI710560B (zh) * 2015-11-03 2020-11-21 美商施萬生物製藥研發Ip有限責任公司 用於治療呼吸疾病之jak激酶抑制劑化合物

Also Published As

Publication number Publication date
TWI808083B (zh) 2023-07-11
KR20200003121A (ko) 2020-01-08
AU2018261591A1 (en) 2019-11-07
EP3619208A1 (en) 2020-03-11
EP3619208B1 (en) 2023-06-07
PH12019502425A1 (en) 2020-06-29
TW201900643A (zh) 2019-01-01
CN110603255A (zh) 2019-12-20
US20180311223A1 (en) 2018-11-01
RU2019138700A (ru) 2021-06-02
WO2018204236A1 (en) 2018-11-08
CN110603255B (zh) 2023-02-10
JP2020518582A (ja) 2020-06-25
US10251874B2 (en) 2019-04-09
MX2019012945A (es) 2019-12-16
RU2019138700A3 (cg-RX-API-DMAC7.html) 2022-01-26
MX389014B (es) 2025-03-20
CA3059790A1 (en) 2018-11-08
AU2018261591B2 (en) 2021-09-02
EP3619208C0 (en) 2023-06-07
SG11201909376TA (en) 2019-11-28
JP7096268B2 (ja) 2022-07-05

Similar Documents

Publication Publication Date Title
PH12019502425A1 (en) Crystalline forms of a jak inhibitor compound
PH12019502345A1 (en) Methods of treatment using a jak inhibitor compoud
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MX2021006283A (es) Derivados heteroaromáticos para uso como regulador, método de preparación de los mismos y uso de los mismos.
PH12019501985A1 (en) Fused imidazo-piperidine jak inhibitors
MX2023004309A (es) Inhibidores de quinasa alk2 que contienen imidazol.
TN2017000075A1 (en) Compounds and compositions as raf kinase inhibitors
TN2016000268A1 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2.
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
PH12020551014A1 (en) Amino-fluoropiperidine derivatives as kinase inhibitor
PH12020551013A1 (en) Oxy-fluoropiperidine derivative as kinase inhibitor
NZ729005A (en) Aminopyrimidinyl compounds as jak inhibitors
MY195427A (en) Jak Kinase Inhibitor Compounds for Treatment of Respiratory Disease
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MX2016016528A (es) Inhibidores de fosfatidilinositol 3-quinasa.
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
NZ726638A (en) Phosphatidylinositol 3-kinase inhibitors
NZ711424A (en) Pyridine derivatives as soft rock inhibitors
AR096543A1 (es) INHIBIDORES DE QUINASA PI3 d Y g SELECTIVOS DUALES
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
MX2016009352A (es) Inhibidores de quinasa a base de quinolina.
HK1209105A1 (en) Vegfr3 inhibitors
MX2016010272A (es) Derivado de indolona sustituido por pirrol, metodo de preparacion del mismo, composicion que comprende el mismo y uso del mismo.
HK1209104A1 (en) Vegfr3 inhibitors